Introduction {#s1}
============

The human intestine is populated by an estimated 10^14^ microbes comprising over 1000 bacterial phylotypes ([@bib20]). The overall composition of the intestinal microbiota is determined by a number of factors, including host genetics, environment, diet and hygiene ([@bib1]; [@bib16]). These bacteria play important roles in host biology by maintaining intestinal homeostasis, barrier function, immunity and metabolic function ([@bib4]; [@bib15]). Perturbations or imbalances in the microbiome (microbial dysbiosis) are linked to a number of disease pathologies such as inflammatory bowel disease ([@bib7] [@bib14]), obesity ([@bib2]; [@bib3]), and colorectal cancers (CRCs; [@bib8]; [@bib16]).

CRC is a complex disease arising from the sequential accumulation of somatic mutations and epigenetic alterations. Activating mutations in the *K-ras* oncogene, as well as the loss of tumor suppressor genes like *p53* (*TP53*) and adenomatous polyposis coli (*APC*), contribute to the tumorigenic transformation of normal colonic epithelium ([@bib29]; [@bib11] [@bib23]). In addition to genetic factors, microbial dysbiosis, such as altered bacterial diversity, is strongly associated with the development of CRC ([@bib16]). However, despite numerous longitudinal studies comparing intestinal microbial communities over time ([@bib25]), and across various cancer stages ([@bib19] [@bib6] [@bib24]), there is limited information on the contribution of specific bacteria to CRC development.

To identify potential associations between inflammatory microorganisms and gastrointestinal cancers, [@bib5] first performed RNA sequencing (RNA-seq) on a limited number of tumor and matched normal tissue samples. Initial observations indicated a striking overrepresentation of *Fusobacterium nucleatum* sequences in carcinoma samples compared to controls. To confirm these findings, [@bib5]) assessed the relative abundance of *Fusobacterium* in a larger cohort of tumor and matched normal biopsy samples. In Figure 2, the authors performed quantitative real-time PCR (qPCR) on genomic DNA (gDNA) isolated from an additional 88 colorectal carcinoma (CRC) specimens and adjacent matched control tissues. *Fusobacterium* abundance was observed to be significantly higher in the tumor samples compared to matching control samples. This key experiment will be replicated in Protocol 1.

Similar findings confirming the higher relative abundance of *Fusobacterium* in CRC tumor tissues compared to control biopsies have been reported by other investigators ([@bib18]; [@bib21]; [@bib30]; [@bib27]). In fact, the study by [@bib18] is considered a co-discovery of this phenomenon. [@bib21] successfully validated the association between *Fusobacterium* and CRC in a set of matched CRC tumor and normal human colon tissue samples using both pyrosequencing and qPCR analysis of the *16S* bacterial rRNA gene. Findings by [@bib22] further confirm this trend, as this group observed a significantly higher presence of *F. nucleatum* in mucosal samples from the CRC patients compared to the healthy subjects (as opposed to matched tissue biopsies). Recent studies have also reported a higher presence of *Fusobacterium* species in human colonic adenomas (polyps) and in stool samples from adenoma and tumor carcinoma patients compared to healthy subjects ([@bib18]; [@bib17]; [@bib21]). Furthermore, other studies have expanded these findings to identify potential mechanisms of action of *F. nucleatum* during tumorigenesis ([@bib26]; [@bib13]). [@bib26] also indirectly confirm a higher abundance of *Fusobacterium* in CRC patients by measuring higher *F. nucleatum* FadA mRNA expression relative to healthy controls.

Materials and methods {#s2}
=====================

Unless otherwise noted, all protocol information was derived from the original paper, references from the original paper, or information obtained directly from the authors. An asterisk (\*) indicates data or information provided by the Reproducibility Project: Cancer Biology core team. A hashtag (\#) indicates information provided by the replicating lab.

Protocol 1: quantitative PCR for amplification of *F. nucleatum* from matched normal and tumor human colon cancer specimens {#s2-1}
---------------------------------------------------------------------------------------------------------------------------

This protocol utilizes quantitative PCR to test the relative abundance of *F. nucleatum* DNA in gDNA isolated from matched normal and tumor human colon cancer specimens. It is a replication of Figure 2.

### Sampling {#s2-1-1}

-   This experiment will include 40 matched samples for a final power of 87.26%.See power calculations for details.

-   Each patient sample has two cohorts:Cohort 1: Colon tumor sample (*n* = 40)Cohort 2: Matched normal tissue within the same individual (*n* = 40)Cohort 3: Age/ethnicity-matched normal tissue from additional control individuals (*n* = 40)

-   Tissue is collected during surgery (either partial colectomy, ileocolectomy, colorectal resection, or proctocolectomy) from tumor tissue, adjacent normal tissue, or from normal controls. Samples are frozen on liquid nitrogen within 30 min after extractions. Diagnosis is confirmed by a pathologist using histological sections from each sample.

-   Quantitative PCR will be performed for each sample two independent times in technical triplicate for the following:*F. nucleatum* DNAProstaglandin transporter---reference gene

### Materials and reagents {#s2-1-2}

ReagentManufacturerCatalog \#CommentsFrozen human colon tumor samples\
and matched normal samples^\#^iSpecimenData include age, gender, ethnicity,\
diagnosis, histopathology reportGentra Puregene Genomic\
DNA extraction kitQiagen158667Replaces Qiagen 69504PicoGreen Assay^\#^Life TechnologiesP7589Spectrophotometer^\#^NanoDropND1000384-well optical PCR plate^\#^Phoenix ResearchMPS-3898Fusobacteria forward qPCR primerPart of a custom-designed\
Taqman primer/probe set\
(Applied Biosystems)CAACCATTACTTTAACTCTA\
CCATGTTCAFusobacteria reverse qPCR primerGTTGACTTTACAGAAGGAGA\
TTATGTAAAAATCFusobacteria FAM probeTCAGCAACTTGTCCTTCTTGA\
TCTTTAAATGAACC^†^PGT forward qPCR primerPart of a custom-designed\
Taqman primer/probe set\
(Applied Biosystems)\
\
\
ATCCCCAAAGCACCTGGTTTPGT reverse qPCR primerAGAGGCCAAGATAGTCCTG\
GTAAPGT FAM probeCCATCCATGTCCTCATCTCTaqMan Universal Master MixABI^\#^4304437qPCR thermal cycling systemABI^\#^43514057900HT system[^1]

### Procedure {#s2-1-3}

1.  Obtain \~40 sets from frozen human CRC tumors with matched normal control, and an additional control group of age/ethnicity-matched tissue from healthy individuals.Tissue will have been flash-frozen in liquid nitrogen very soon after harvest.Pathological data showing positive diagnosis for CRC will be included with samples.

2.  Extract gDNA using Gentra Puregene genomic DNA extraction kit according to manufacturer's instructions.

3.  Quantify gDNA concentration by Nanodrop spectrophotometer.

4.  Assemble 20 μL qPCR reactions in a 384-well optical PCR plate. Each sample is assayed in triplicate for each primer/probe set. Each reaction contains:5 ng of gDNA18 μM of each primer5 μM of probe1 X final concentration of TaqMan Universal Master Mix

5.  Perform amplification and detection of DNA using the following reaction conditions:2 min at 50°C10 min at 95°C40 cycles of 15 s at 95°C and 1 min at 60°C.

6.  Calculate cycle threshold using the automated settings. Analyze and compute ΔΔ*C*~T~ values by normalizing to prostaglandin transporter reference gene.The mean ΔΔ*C*~T~ values from the technical replicates from the tumor and normal sample will be used to calculate the ratio of tumor versus normal for each matched biopsy.

7.  Repeat steps 3--5 for each sample a second time.The mean ratios of ΔΔ*C*~T~ values in tumor versus normal sample from the two independent experimental replicates will be calculated for each matched biopsy.

### Deliverables {#s2-1-4}

-   Data to be collected:Descriptive data of gDNA samples including: patient sample age/sex, ethnicity, and % area of the tumor involved with necrosis.Purity (*A*~260/280~ and *A*~260/230~ ratios) and concentration of isolated total gDNA from tumor biopsies.Raw qRT-PCR values, as well as analyzed ΔΔ*C*~T~ values for each tumor and matched biopsy sample. Bar graph of mean relative abundance of *F. nucleatum* in tumor versus normal colorectal samples (compare to Figure 2A).

### Confirmatory analysis plan {#s2-1-5}

This replication attempt will perform the statistical analysis listed below:

-   Statistical analysis of replication data:Note: At the time of analysis, we will perform the Shapiro--Wilk test and generate a quantile--quantile (*q*--*q*) plot to assess the normality of the data. If the data appear skewed, we will perform the appropriate transformation in order to proceed with the proposed statistical analysis. If this is not possible, we will perform the equivalent nonparametric test (e.g., Wilcoxon-signed rank test).One-sample Student's *t*-test using the log of the mean ratios of ΔΔ*C*~T~ values from the two independent experimental replicates, tumor ΔΔ*C*~T~/matched within individual controls compared to a mean value of zero.

-   Additional exploratory analysis:Two Student's *t*-tests with Bonferroni correction comparing absolute values from:Mean tumor *Fusobacterium* abundance versus within subject matched control (paired)Mean tumor *Fusobacterium* abundance versus healthy matched control (unpaired)

-   Meta-analysis of original and replication attempt effect sizes:Compute the effect size, compare it against the effect size in the original paper and use a random effects meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.

### Known differences from the original study {#s2-1-6}

All known differences are listed in the \'Materials and reagents\' section with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design. We have added an additional control of matched gDNA from healthy individuals.

### Provisions for quality control {#s2-1-7}

The sample purity (*A*~260/280~ and *A*~260/230~ ratios) of the isolated gDNA from each sample will be reported. All of the raw data, including the analysis files, will be uploaded to the project page on the OSF (<https://osf.io/v4se2>) and made publically available.

Power calculations {#s2-2}
------------------

For a detailed breakdown of all power calculations, see spreadsheet at [https://osf.io/yadgq/](https://osf.io/yadgq/?view_only=748a4e8faa854109a9082ddebd72d8b6)

Protocol 1 {#s2-3}
----------

### Summary of original data {#s2-3-1}

-   Note: Data estimated from graph reported in Figure 2.

SampleLog (mean)*N*1‑1.578722‑1.195723‑0.927724‑0.876625‑0.519226‑0.446827‑0.412828‑0.314929‑0.2936210‑0.2681211‑0.2766212‑0.2383213‑0.234214‑0.2215‑0.1787216‑0.1703217‑0.1617218‑0.1362219‑0.0681220‑0.02982210.0342220.01282230.00952240.0172250.02132260.02132270.02552280.01282290.0172300.01282310.0172320.02552330.02132340.03012350.0342360.05552370.13622380.14472390.17452400.19152410.22420.20862430.2172440.22132450.25962460.40432470.44682480.45112490.46812500.49792510.50642520.50212530.5492540.57872550.57872560.58722570.60852580.62132590.65532600.69792610.72342620.76172630.80432640.82982650.9662660.96172671.00422681.01282691.0172701.02552711.06812721.05962731.08512741.12342751.19582761.31492771.31492781.40852791.62982801.75752811.7832821.87232831.94042841.98328522862.25532872.42982882.47232892.47232902.55322912.67232922.68932932.90642943.05962953.24252963.34472973.58722983.82994.2612

Test family {#s2-4}
-----------

-   Ratio one-sample *t*-test: a~error~ = 0.05, µ = 0.

Power calculations {#s2-5}
------------------

-   Ratio *t*-test and power calculations were performed with R software, version 3.1.2 ([@bib28]).

MeanEffect\
size *d*A priori powerTotal sample sizeRatio0.758938380.502456887.26%40\*[^2]

Additional exploratory analysis {#s2-6}
-------------------------------

### Test family {#s2-6-1}

-   Paired Student's *t*-test (two-tailed): a~error~ = 0.025.

### Power calculations {#s2-6-2}

-   Sensitivity calculations were performed with G\*Power software, version 3.1.7 ([@bib10]).

Group 1Group 2Detectable effect\
size *d*A priori powerTotal\
sample\
sizeTumor sampleAdjacent matched\
control0.5038480%40

### Test family {#s2-6-3}

-   Independent Student's *t*-test (two-tailed): a~error~ = 0.025.

### Power calculations {#s2-6-4}

-   Sensitivity calculations were performed with G\*Power software, version 3.1.7. ([@bib10]).

Group 1Group 2Detectable effect\
size *d*A priori powerTotal\
sample\
sizeTumor sampleHealthy\
individual matched\
control0.700780%40
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your work entitled \"Registered report: *Fusobacterium nucleatum* infection is prevalent in human colorectal carcinoma\" for consideration by *eLife*. Your article has been reviewed by four peer reviewers, and the evaluation has been overseen by a guest Reviewing Editor and Sean Morrison as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The project goal is to test the reproducibility of the results in the Castellarin et al., 2012 paper in which *Fusobacterium* was associated with CRC by qPCR detection of *Fusobacterium* (versus a reference gene) in DNA isolated from colon tumors compared to matched uninvolved tissue and normal tissue from age-matched controls.

Essential revisions:

After discussion among all reviewers, the key clarifications requested are to define in more detail the source of the populations to be studied. Information about how subjects and controls will be recruited, how disease will be defined (including histopathology), how samples will be obtained as well as length and type of storage of samples should be explicitly stated. How many healthy individuals will be included in the study? Are tissues from healthy controls obtained through biopsy or colorectal resection? The title page should be corrected to reflect that the project is human subjects research.

\[Editors' note: a previous version of this study was rejected after peer review, but the authors submitted for reconsideration. The previous decision letter after peer review is shown below.\]

Thank you for submitting your work entitled \"Registered report: *Fusobacterium nucleatum* infection is prevalent in human colorectal carcinoma\" for consideration at *eLife*. Your Registered Report has been evaluated by Sean Morrison (Senior editor) and a guest Reviewing Editor with appropriate expertise, and the decision was reached after discussions between the two of us. We regret to inform you that this version of the Registered Report will not be considered further for publication in *eLife*.

Unfortunately the proposed replication misses at least one key issue in this area of work. There are several reports of finding excess *Fusobacterium* in a subset of colon cancers versus matched normal and we have two major concerns:

1\) Normal tissues from cancer hosts are not normal controls for these experiments (the authors would need to identify a bank of appropriate colonoscopy control biopsies or age-match normal tissues from rapid autopsies).

2\) The key result that needs to be replicated is whether *Fusobacterium nucleatum* versus other species induce tumorigenesis in tumor-susceptible murine models. Addressing this key aspect of *Fusobacterium* biology by the Reproducibility Project is essential before we can move forwards with further in-depth review. Absent this experiment, it will not be possible to conclude whether they key claims in the paper in question are reproducible.

10.7554/eLife.10012.003

Author response

Essential revisions:

After discussion among all reviewers, the key clarifications requested are to define in more detail the source of the populations to be studied. Information about how subjects and controls will be recruited, how disease will be defined (including histopathology), how samples will be obtained as well as length and type of storage of samples should be explicitly stated. How many healthy individuals will be included in the study? Are tissues from healthy controls obtained through biopsy or colorectal resection? The title page should be corrected to reflect that the project is human subjects' research.

We have added clarifications to the manuscript to address these questions, but have answered more specifically below:

1\) We will obtain tumor tissue samples from, iSpecimen located in Boston, MA. They have provided us with the information you requested.

2\) The source population is defined as in the original manuscript: 50 years of age ( /- 5-10 years), normal control donors are matched for age, gender, and ethnicity and are collected from patients during surgery (either partial colectomy, ileocolectomy, colorectal resection or proctocolectomy). Samples are frozen in liquid nitrogen within 30 minutes of extraction.

3\) iSpecimen represents multiple medical centers which use in-house pathologists to conduct histology on sections of all samples to confirm diagnosis.

4\) The kit for gDNA extraction is a similar kit from Qiagen and will quantify gDNA using a NanoDrop.

Since the Registered Report does not involve using human tissue, but rather the proposed plan to use it, we typically do not list the Registered Report as a Human Subject study. However, we will include human subjects research information with the Final Report of replication results.

\[Editors' note: the author responses to the previous round of peer review follow.\]

Unfortunately the proposed replication misses at least one key issue in this area of work. There are several reports of finding excess Fusobacterium in a subset of colon cancers versus matched normal and we have two major concerns:

1\) Normal tissues from cancer hosts are not normal controls for these experiments (the authors would need to identify a bank of appropriate colonoscopy control biopsies or age-match normal tissues from rapid autopsies).

Adding additional aspects not included in the original study can be of scientific interest, and can be included if it is possible to balance them with the main aim of this project: to perform a direct replication of the original experiment(s). As such, we agree with the editors that there is scientific interest in including these additional control samples. We have added this control to the manuscript and made appropriate adjustments to our power calculations.

2\) The key result that needs to be replicated is whether Fusobacterium nucleatum versus other species induce tumorigenesis in tumor-susceptible murine models. Addressing this key aspect of Fusobacterium biology by the Reproducibility Project is essential before we can move forwards with further in-depth review. Absent this experiment, it will not be possible to conclude whether they key claims in the paper in question are reproducible.

We agree that investigating whether this *Fusobacterium* ssp. in particular is responsible for inducing tumorigenesis is a critical extension of the Castellarin study. However, this project focuses on direct replication of the experiments as detailed in the original report and with information provided by the original authors to understand the reproducibility of the reported results. Aspects of an experiment not included in the original study are occasionally added (such as negative controls, reagent verification, etc.) to ensure the quality of the research, but are only included if it is possible to balance them with the main aim of this project: to perform a direct replication of the original experiment(s). We feel that the addition of this experiment, despite it being an important question in the field, is outside of the scope of this project.

[^1]: ^†^Note: Probe sequence from original manuscript incorrect. Correct sequence seen here from [@bib12].

[^2]: \*Forty total ratios (40 tumor 40 matched controls) will be used.
